OptiNose US, Inc., a leading player in the biopharmaceutical industry, is headquartered in the United States and focuses on innovative solutions for patients with chronic sinusitis and other nasal conditions. Founded in 2010, the company has made significant strides in developing unique delivery systems that enhance the efficacy of medications, particularly through its proprietary intranasal technology. OptiNose's core products, including the XHANCE® nasal spray, stand out for their ability to deliver medication directly to the nasal passages, improving patient outcomes and adherence. With a commitment to advancing nasal drug delivery, OptiNose has established a strong market position, recognised for its contributions to the treatment of chronic rhinosinusitis. The company continues to expand its operational reach, aiming to transform the landscape of nasal therapeutics.
We don't have data for OptiNose US, Inc., but we can show you information about their parent organization instead.
View parent company